Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The role of kinase inhibitors in the treatment of patients with acute myeloid leukemia.

Smith CC, Shah NP.

Am Soc Clin Oncol Educ Book. 2013:313-8. doi: 10.1200/EdBook_AM.2013.33.313. Review.

2.

The role of quizartinib in the treatment of acute myeloid leukemia.

Ostronoff F, Estey E.

Expert Opin Investig Drugs. 2013 Dec;22(12):1659-69. doi: 10.1517/13543784.2013.842973. Epub 2013 Sep 26. Review.

PMID:
24070241
3.

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML.

Sexauer A, Perl A, Yang X, Borowitz M, Gocke C, Rajkhowa T, Thiede C, Frattini M, Nybakken GE, Pratz K, Karp J, Smith BD, Levis M.

Blood. 2012 Nov 15;120(20):4205-14. doi: 10.1182/blood-2012-01-402545. Epub 2012 Sep 25.

4.

Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP.

Nature. 2012 Apr 15;485(7397):260-3. doi: 10.1038/nature11016.

5.

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.

Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F.

Expert Opin Investig Drugs. 2014 Jul;23(7):943-54. doi: 10.1517/13543784.2014.911839. Epub 2014 Apr 21. Review.

6.

Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.

Levis M.

Future Oncol. 2014;10(9):1571-9. doi: 10.2217/fon.14.105. Review.

PMID:
25145428
7.

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M.

J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3.

8.

Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.

Alvarado Y, Kantarjian HM, Luthra R, Ravandi F, Borthakur G, Garcia-Manero G, Konopleva M, Estrov Z, Andreeff M, Cortes JE.

Cancer. 2014 Jul 15;120(14):2142-9. doi: 10.1002/cncr.28705. Epub 2014 Apr 15.

9.

FLT3 inhibitors in AML: are we there yet?

Sudhindra A, Smith CC.

Curr Hematol Malig Rep. 2014 Jun;9(2):174-85. doi: 10.1007/s11899-014-0203-8. Review.

PMID:
24682858
10.

Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.

Wang F, Liu Z, Zeng J, Zhu H, Li J, Cheng X, Jiang T, Zhang L, Zhang C, Chen T, Liu T, Jia Y.

Leuk Res. 2015 Dec;39(12):1421-7. doi: 10.1016/j.leukres.2015.09.016. Epub 2015 Sep 18.

PMID:
26505133
11.

Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.

Keegan K, Li C, Li Z, Ma J, Ragains M, Coberly S, Hollenback D, Eksterowicz J, Liang L, Weidner M, Huard J, Wang X, Alba G, Orf J, Lo MC, Zhao S, Ngo R, Chen A, Liu L, Carlson T, Quéva C, McGee LR, Medina J, Kamb A, Wickramasinghe D, Dai K.

Mol Cancer Ther. 2014 Apr;13(4):880-9. doi: 10.1158/1535-7163.MCT-13-0858. Epub 2014 Feb 13.

12.

FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.

Fathi AT, Chabner BA.

Oncologist. 2011;16(8):1162-74. doi: 10.1634/theoncologist.2011-0084. Epub 2011 Jul 17.

13.

Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.

Swords R, Freeman C, Giles F.

Leukemia. 2012 Oct;26(10):2176-85. doi: 10.1038/leu.2012.114. Epub 2012 Apr 27. Review.

PMID:
22614177
14.

Leukemogenic potency of the novel FLT3-N676K mutant.

Huang K, Yang M, Pan Z, Heidel FH, Scherr M, Eder M, Fischer T, Büsche G, Welte K, von Neuhoff N, Ganser A, Li Z.

Ann Hematol. 2016 Apr;95(5):783-91. doi: 10.1007/s00277-016-2616-z. Epub 2016 Feb 19.

PMID:
26891877
15.

A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.

Hou P, Wu C, Wang Y, Qi R, Bhavanasi D, Zuo Z, Dos Santos C, Chen S, Chen Y, Zheng H, Wang H, Perl A, Guo D, Huang J.

Cancer Res. 2017 Aug 15;77(16):4402-4413. doi: 10.1158/0008-5472.CAN-16-1627. Epub 2017 Jun 16.

PMID:
28625976
16.

Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase.

Yang X, Sexauer A, Levis M.

Br J Haematol. 2014 Jan;164(1):61-72. doi: 10.1111/bjh.12599. Epub 2013 Oct 10.

17.

Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.

Giri S, Hamdeh S, Bhatt VR, Schwarz JK.

J Natl Compr Canc Netw. 2015 May;13(5):508-14.

PMID:
25964636
18.

FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Grunwald MR, Levis MJ.

Int J Hematol. 2013 Jun;97(6):683-94. doi: 10.1007/s12185-013-1334-8. Epub 2013 Apr 24. Review.

PMID:
23613268
19.

Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.

Zhang W, Gao C, Konopleva M, Chen Y, Jacamo RO, Borthakur G, Cortes JE, Ravandi F, Ramachandran A, Andreeff M.

Clin Cancer Res. 2014 May 1;20(9):2363-74. doi: 10.1158/1078-0432.CCR-13-2052. Epub 2014 Mar 11.

20.

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.

Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N.

PLoS One. 2013;8(2):e56473. doi: 10.1371/journal.pone.0056473. Epub 2013 Feb 21.

Supplemental Content

Support Center